Under a settlement with the Federal Trade Commission, a melanoma-detection app vendor has been barred from making further deceptive health claims about his products available for sale online in the Apple and Google app stores.
According to FTC, Avrom Lasarow is now prohibited from making any misleading or unsubstantiated claims about the health benefits or efficacy of any product or service, including that a device detects or diagnoses melanoma. Earlier this year, FTC charged U.K.-based Lasarow and his companyL Health Ltd.with false advertising regarding the Mole Detective family of apps and their ability to detect melanoma or the risk of melanoma.
Register or login for access to this item and much more
All Health Data Management content is archived after seven days.
Community members receive:
- All recent and archived articles
- Conference offers and updates
- A full menu of enewsletter options
- Web seminars, white papers, ebooks
Already have an account? Log In
Don't have an account? Register for Free Unlimited Access